+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating different dose levels of Brenipatide in adults with moderate-to-severe Chronic Obstructive Pulmonary Disease COPD. The study aims to assess the safety and effectiveness of Brenipatide compared to a placebo over approximately one year. This Phase 2 trial focuses on how the drug works alongside standard care in people with COPD who have a history of smoking and recent exacerbations. Participants are randomly assigned to receive either a low dose or high dose of Brenipatide or a placebo, all given by subcutaneous injection. All groups continue their standard care therapy, which may include long-acting bronchodilators or inhaled corticosteroids. The treatment period lasts 52 weeks, during which participants receive the study drug or placebo alongside their regular medications. Throughout the study, participants will have lung function tests measuring forced expiratory volume FEV1 before bronchodilator use at baseline and at several weeks up to week 52. Researchers will also monitor COPD exacerbation rates and quality of life using specific questionnaires. Safety and treatment effects are assessed regularly to understand how Brenipatide performs in managing COPD symptoms and lung function over one year.

Age: 40Years - 75YearsAll GendersPhase 2
127 locations
E

Actively Recruiting

Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.

Age: 18Years - 99YearsAll GendersPhase 3
686 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are conducting a Phase 2b study to evaluate the safety, immune response, and effectiveness of a new bivalent protein vaccine against Respiratory Syncytial Virus RSV and Human Metapneumovirus HMPV in adults aged 60 years and older. This randomized, placebo-controlled, observer-blind trial aims to prevent lower respiratory tract diseases caused by these viruses in an elderly population. The study is sponsored by Sanofi and focuses on vaccine prevention in healthy volunteers. Participants will receive a single intramuscular injection of either the bivalent RSVHMPV protein vaccine or a matching placebo. The study includes an initial Safety Lead-in Cohort of 200 participants randomized 11 to vaccine or placebo, followed by a Main Cohort of 7,800 participants also randomized 11 after safety review. Both groups receive only one dose and are monitored over time to assess vaccine effects and safety. Throughout the study, participants will be monitored for respiratory infections caused by RSV and HMPV from 14 days up to 12 months after vaccination. Researchers will also evaluate immune responses by measuring antibody levels before vaccination and at multiple time points afterward. Safety assessments include tracking adverse events immediately after vaccination and for up to one year. The total participation duration spans about 12 months, covering vaccination, follow-up visits, and safety monitoring.

Age: 60Years +All GendersPhase 2
21 locations